PRA Health Sciences (PRAH) Receives Analyst Rating

PRA Health Sciences (PRAH) has an average broker rating of 1.29, which is interpreted as a Strong Buy, as rated by 7 equity analysts. Nonetheless, 6 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

PRA Health Sciences (PRAH) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $60 and the lowest price target forecast is $55. The average forecast of all the analysts is $58 and the expected standard deviation is $2.12.


Also, Major Brokerage house, UBS downgrades its ratings on PRA Health Sciences (NASDAQ:PRAH). In the latest research report, UBS raises the target price from $50 per share to $55 per share. According to the latest information available, the shares are now rated Neutral by the analysts at the agency. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on September 6, 2016.

PRA Health Sciences (NASDAQ:PRAH): After opening at $51.92, the stock dipped to an intraday low of $51.71 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $53.95 and the buying power remained strong till the end. The stock closed at $53.57 for the day, a gain of 3.54% for the day session. The total traded volume was 648,093. The stocks close on the previous trading day was $51.74.

PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company performs an array of services across the spectrum of clinical development programs, from the filing of investigational new drug (INDs) and similar regulatory applications to conducting all phases of clinical trials. Its service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *